Lunai Bioworks Unveils AI-Driven Platform to De-Risk Drug Discovery in Complex Diseases

Lunai Bioworks Inc - Identifies Three Parkinson's Disease Subtypes

Lunai Bioworks Inc - Prioritized Drug Targets in $13 Bln Parkinson's Market

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritizes Drug Targets

BRIEF-Lunai Bioworks - Enters Sales Agreement With Dawson James Securities - SEC Filing

Lunai Bioworks Inc - May Offer & Sell Stock up to $11.70 Mln - SEC Filing

Lunai Bioworks Raises $3.1 Million in Private Placement of Shares and Warrants

Lunai Bioworks Secures First Licensing LOI for Immune Cell Therapy

Lunai Bioworks Secures First Licensing Loi Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Lunai Bioworks Achieves Complete Regression of Both Primary and Metastatic Pancreatic Tumors in Preclinical Humanized Models, Marking a Breakthrough in Allogeneic Cancer Immunotherapy

Lunai Bioworks Announces Breakthrough Allogeneic Cell Therapy Reversing Pancreatic Tumors in Preclinical Models

Lunai Bioworks Regains Nasdaq Compliance After Holding Annual Meeting

Lunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models

Lunai Bioworks Inc. held annual shareholder meeting

Lunai Bioworks Unveils AI Platform for Early Detection of Neurotoxic Compounds

Lunai Bioworks Receives Nasdaq Notice for Market Value Noncompliance

Lunai Bioworks Inc. Announces Landmark Study Identifying Prognostic Biomarkers in Duchenne Muscular Dystrophy

Lunai Bioworks Regains Nasdaq Compliance with Minimum Bid Price Requirement

Lunai Bioworks Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Lunai Bioworks Signs First Commercial Contract for AI-Based Early Alzheimer's Detection Program